The purpose of this study is to assess the safety and immunogenicity of one dose of A/H1N1
non-adjuvanted pandemic vaccine to support registration of the vaccine in India.
- To describe the safety profile (injection site reactions and systemic events) of the
vaccine within 21 days following vaccination, and serious adverse events throughout the
study in all subjects
- To describe the immune response to the vaccine 21 days after vaccination by
hemagglutination inhibition (HAI) testing in all subjects
- To describe the antibody persistence 6 months after vaccination by HAI testing in all